Background: Allergic rhinitis (AR) is recognized as a major health problem worldwide, and its prevalence depends on the age range of the subjects. The aims of this study were to determine the current prevalence of AR, effects of age on the prevalence of IgE sensitization to inhalant allergens, and serum total IgE levels in Japanese subjects. Methods: We conducted a survey of 1,540 subjects between 20 and 49 years of age in 2006 and 2007 and examined the prevalence of AR and sensitization to 7 common aeroallergens. We measured serum total IgE and specific IgE to 7 aeroallergens. AR was determined based on symptoms, predominantly in the nose and eyes, caused by aeroallergens as mentioned in a questionnaire and sensitization to any of the 7 aeroallergens as assessed by measurement of serum specific IgE. Results: The prevalence of AR was 44.2% (681 of the 1,540 subjects) and there was no difference among age decades. Of the 1,540 subjects, 1,073 (69.7%) were sensitized to at least 1 of the 7 aeroallergens. The most common allergen in AR was Japanese cedar pollen (89.6%, 610 of the 681 with AR) in all the age decades examined. The sensitization rate to mites was significantly higher in the younger subjects. Conclusion: Our data suggest that the prevalence of AR between 20 and 49 years of age has increased by nearly 10% during the last 10 years. Cedar pollen and mites were predominant allergen sources among the 7 aeroallergens in the Japanese population.

Keywords:
Aeroallergen, Allergic rhinitis, Dust mite, Specific human IgE, Japanese cedar pollen
1.
Bousquet J, Van Cauwenberge P, Khaltaev N; Aria Workshop Group, World Health Organization: Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:S147–S334.
2.
Skoner DP: Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001;108:S2–S8.
3.
Rimpelä AH, Savonius B, Rimpelä MK, Haahtela T: Asthma and allergic rhinitis among Finnish adolescents in 1977–1991. Scand J Soc Med 1995;23:60–65.
4.
Meltzer EO: The prevalence and medical and economic impact of allergic rhinitis in the United States. J Allergy Clin Immunol 1997;99:S805–S828.
5.
Greisner WA 3rd, Settipane RJ, Settipane GA: Natural history of hay fever: a 23-year follow-up of college students. Allergy Asthma Proc 1998;19:271–275.
6.
Hesselmar B, Aberg B, Eriksson B, Aberg N: Allergic rhinoconjunctivitis, eczema, and sensitization in two areas with differing climates. Pediatr Allergy Immunol 2001;12:208–215.
7.
Okuda M: Epidemiology of Japanese cedar pollinosis throughout Japan. Ann Allergy Asthma Immunol 2003;91:288–296.
8.
Ishizaki T, Koizumi K, Ikemori R, Ishiyama Y, Kushibiki E: Studies of prevalence of Japanese cedar pollinosis among the residents in a densely cultivated area. Ann Allergy 1987;58:265–270.
9.
Sakurai Y, Nakamura K, Teruya K, et al: Prevalence and risk factors of allergic rhinitis and cedar pollinosis among Japanese men. Prev Med 1998;27:617–622.
10.
Kaneko Y, Motohashi Y, Nakamura H, Endo T, Eboshida A: Increasing prevalence of Japanese cedar pollinosis: a meta-regression analysis. Int Arch Allergy Immunol 2005;136:365–371.
11.
Okawa T, Konno A, Yamakoshi T, Numata T, Terada N, Shima M: Analysis of natural history of Japanese cedar pollinosis. Int Arch Allergy Immunol 2003;131:39–45.
12.
Naclerio RM: Allergic rhinitis. N Engl J Med 1991;325:860–869.
13.
Sherrill D, Stein R, Kurzius-Spencer M, Martinez F: On early sensitization to allergens and development of respiratory symptoms. Clin Exp Allergy 1999;29:905–911.
14.
Sly RM: Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol 1999;82:233–248.
15.
Strachan D, Sibbald B, Weiland S, et al: Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Allergy Immunol 1997;8:161–176.
16.
Devenny A, Wassall H, Ninan T, Omran M, Khan SD, Russell G: Respiratory symptoms and atopy in children in Aberdeen: questionnaire studies of a defined school population repeated over 35 years. BMJ 2004;329:489–490.
17.
Passalacqua G, Durham SR; Global Allergy and Asthma European Network: Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007;119:881–891.
18.
Nelson HS: Allergen immunotherapy: where is it now? J Allergy Clin Immunol 2007;119:769–779.
19.
Purello-D’Ambrosio F, Gangemi S, Merrendino RA, et al: Prevention of new sensitizations in monosensitizied subjects submitted to specific immunotherapy or not. A retrospecific study. Clin Exp Allergy 2001;31:1295–1302.
20.
Squillace SP, Sporik RB, Rakes G, et al: Sensitization to dust mites as a dominant risk factor for asthma among adolescents living in central Virginia. Multiple regression analysis of a population-based study. Am J Respir Crit Care Med 1997;156:1760–1764.
21.
Settipane RJ, Settipane GA: IgE and the allergy-asthma connection in the 23-year follow-up of Brown University students. Allergy Asthma Proc 2000;21:221–225.
22.
Kim JS, Ouyang F, Pongracic JA, et al: Dissociation between the prevalence of atopy and allergic disease in rural China among children and adults. J Allergy Clin Immunol 2008;122:929–935.
23.
Jaén A, Sunyer J, Basagaña X, et al: Specific sensitization to common allergens and pulmonary function in the European Community Respiratory Health Survey. Clin Exp Allergy 2002;32:1713–1719.
24.
Christiani DC, Kern DG: Asthma risk and occupation as a respiratory therapist. Am Rev Respir Dis 1993;148:671–674.
25.
Dimich-Ward H, Wymer ML, Chan-Yeung M: Respiratory health survey of respiratory therapists. Chest 2004;126:1048–1053.
26.
Pechter E, Davis LK, Tumpowsky C, et al: Work-related asthma among health care workers: surveillance data from California, Massachusetts, Michigan, and New Jersey, 1993–1997. Am J Ind Med 2005;47:265–275.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.